Physician profile
Christopher R Gilbert
NPI 1487657243
$2,000.90
in general payments reported to CMS, 2019-2025
22 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $23.72 · 2021: $76.64 · 2022: $482 · 2023: $623 · 2024: $249 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $346.47 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $254.82 | 2022-2025 | |
| Biotronik INC. | $194.88 | 2019-2022 | |
| Boston Scientific Corporation | $187.19 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Baxter Healthcare | $130.15 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $118.40 | 2023-2025 | Repatha |
| Abbott Laboratories | $112.36 | 2023-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $88.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $86.55 | 2022-2023 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $73.26 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $65.32 | 2023-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $56.07 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $53.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.04 | 2019-2025 | Camzyos |
| Irhythm Technologies, INC. | $33.47 | 2022-2023 | Zio Xt Patch |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.97 | 2023 | Rybelsus, Ozempic |
| Cardiva Medical, INC. | $24.71 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Davol INC. | $23.72 | 2020 | |
| Merck Sharp & Dohme LLC | $23.39 | 2022 | |
| Philips North America LLC | $19.99 | 2023 | |
| Sanofi-Aventis U.S. LLC | $19.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.